Optimal Management of Prostate Cancer Based on its Natural Clinical History
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.org..
Prostate cancer is the most common malignancy in males and, despite a marked improvement in diagnostic techniques, a not small percentage of prostate tumours is still diagnosed in advanced stage. It is now clear that prostate cancer passes through distinct phases during its natural history, starting from an initial phase, in which the disease has a locoregional extent, until a very late phase when it becomes refractory to hormone therapy. It is important to distinguish between local disease, in which tumor may be considered localized in the gland and a systemic disease characterized by high tumor burden and/or dissemination of circulating tumour cells. All the prostate cancers, at first diagnosis, are characterized by high sensitivity to the androgen deprivation therapy (ADT); however, during the natural history, after a variable period, they become castration resistant. In the past, few therapy options were available for castration resistant prostate cancer, while at present much more approaches can be employed, both hormone-based therapies and chemotherapy regimens. Hypercastration agents are defined as drugs capable to target the androgenandrogen receptor axis even in castrate resistant conditions. Abiraterone and enzalutamide are the only two hypercastration agents available for clinical use. Osteoclast targeted agents, such as zoledronic acid and denosumab can always been employed, but their use should be limited to the castrate resistant setting. The optimal understanding of all phases characterizing the natural history of prostate cancer may certainly be useful for the selection of the best therapeutic options in prostate cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Current cancer drug targets - 18(2018), 5 vom: 09., Seite 457-467 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Facchini, Gaetano [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 02.08.2019 Date Revised 02.08.2019 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1568009617666170209093101 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM268823545 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM268823545 | ||
| 003 | DE-627 | ||
| 005 | 20231224223353.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1568009617666170209093101 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0896.xml |
| 035 | |a (DE-627)NLM268823545 | ||
| 035 | |a (NLM)28183253 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Facchini, Gaetano |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Optimal Management of Prostate Cancer Based on its Natural Clinical History |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.08.2019 | ||
| 500 | |a Date Revised 02.08.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.org. | ||
| 520 | |a Prostate cancer is the most common malignancy in males and, despite a marked improvement in diagnostic techniques, a not small percentage of prostate tumours is still diagnosed in advanced stage. It is now clear that prostate cancer passes through distinct phases during its natural history, starting from an initial phase, in which the disease has a locoregional extent, until a very late phase when it becomes refractory to hormone therapy. It is important to distinguish between local disease, in which tumor may be considered localized in the gland and a systemic disease characterized by high tumor burden and/or dissemination of circulating tumour cells. All the prostate cancers, at first diagnosis, are characterized by high sensitivity to the androgen deprivation therapy (ADT); however, during the natural history, after a variable period, they become castration resistant. In the past, few therapy options were available for castration resistant prostate cancer, while at present much more approaches can be employed, both hormone-based therapies and chemotherapy regimens. Hypercastration agents are defined as drugs capable to target the androgenandrogen receptor axis even in castrate resistant conditions. Abiraterone and enzalutamide are the only two hypercastration agents available for clinical use. Osteoclast targeted agents, such as zoledronic acid and denosumab can always been employed, but their use should be limited to the castrate resistant setting. The optimal understanding of all phases characterizing the natural history of prostate cancer may certainly be useful for the selection of the best therapeutic options in prostate cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Prostate cancer | |
| 650 | 4 | |a androgen deprivation therapy | |
| 650 | 4 | |a bone metastasis | |
| 650 | 4 | |a hypercastration | |
| 650 | 4 | |a metastatic castration resistant prostatecancer | |
| 650 | 4 | |a natural history. | |
| 650 | 7 | |a AR protein, human |2 NLM | |
| 650 | 7 | |a Androgen Antagonists |2 NLM | |
| 650 | 7 | |a Receptors, Androgen |2 NLM | |
| 700 | 1 | |a Perri, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Misso, Gabriella |e verfasserin |4 aut | |
| 700 | 1 | |a D'Aniello, Carmine |e verfasserin |4 aut | |
| 700 | 1 | |a Scarpati, Giuseppina Della Vittoria |e verfasserin |4 aut | |
| 700 | 1 | |a Rossetti, Sabrina |e verfasserin |4 aut | |
| 700 | 1 | |a Pepa, Chiara Della |e verfasserin |4 aut | |
| 700 | 1 | |a Pisconti, Salvatore |e verfasserin |4 aut | |
| 700 | 1 | |a Unteregger, Gerhard |e verfasserin |4 aut | |
| 700 | 1 | |a Cossu, Alessia |e verfasserin |4 aut | |
| 700 | 1 | |a Caraglia, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Berretta, Massimiliano |e verfasserin |4 aut | |
| 700 | 1 | |a Cavaliere, Carla |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current cancer drug targets |d 2001 |g 18(2018), 5 vom: 09., Seite 457-467 |w (DE-627)NLM120490560 |x 1873-5576 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2018 |g number:5 |g day:09 |g pages:457-467 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1568009617666170209093101 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2018 |e 5 |b 09 |h 457-467 | ||